Links to access each publication and its plain language summary can be found by clicking "Read more"

Want to stay up to date on news from REPRIEVE?

Click here to sign up for the REPRIEVE Insights Newsletter!

May 2, 2024

Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV

Abstract The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) (Aug. 24 issue of NEJM) was a global trial that assessed pitavastatin calcium as compared […]
May 2, 2024

Coronary plaque in asymptomatic people with HIV vs non-HIV asymptomatic community- and symptomatic higher-risk populations

Abstract Background People with HIV (PWH) have a high burden of coronary plaques; however, the comparison to people without known HIV (PwoH) needs clarification. Objectives The […]
April 4, 2024

Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial

Abstract Background  Coronary artery disease (CAD) is a leading cause of death among the 38.4 million people with HIV globally. The extent to which cardiovascular polygenic risk […]
February 21, 2024

Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial

Abstract Importance  Cardiovascular disease (CVD) is increased in people with HIV (PWH) and is characterized by premature noncalcified coronary plaque. In the Randomized Trial to Prevent Vascular […]
January 12, 2024

Risk Factors for Clonal Hematopoiesis of Indeterminate Potential in People with HIV: a report from the REPRIEVE Trial

Abstract Key Points Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. […]
January 8, 2024

CMV IgG is Associated with Physical Function but not Muscle Density in People with HIV

Abstract Background Cytomegalovirus (CMV) seropositivity is associated with poor outcomes, including physical function impairment, in people without HIV. We examined associations between CMV IgG titer and […]
September 28, 2023

Biological and Clinical Implications of the VEGF Coreceptor Neuropilin-1 in HIV

Abstract Plasma VEGF coreceptor neuropilin-1 (NRP-1) had the largest association with coronary plaque in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) proteomics analysis. […]
July 31, 2023

Hepatic steatosis and NAFLD are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV

Abstract Background Hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD), is common among people with HIV (PWH). We present baseline steatosis prevalence and cardiometabolic characteristics among […]
July 23, 2023

Pitavastatin to Prevent Cardiovascular Disease in People with HIV

Abstract Background The risk of cardiovascular disease is increased among persons with human immunodeficiency virus (HIV), so data regarding primary prevention strategies in this population are […]
July 17, 2023

Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People with HIV in the REPRIEVE Cohort

Abstract Background Pericoronary adipose tissue (PCAT) may influence plaque development through inflammatory mechanisms. We assessed PCAT density, as a measure of pericoronary inflammation, in relationship to […]
July 10, 2023

Associations of Muscle Density and Area with Coronary Artery Plaque and Physical Function

Abstract Objective Skeletal muscle quality and mass are important for maintaining physical function during advancing age. We leveraged baseline data from REPRIEVE to evaluate whether paraspinal muscle density […]
April 5, 2023

Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV

Abstract Background Mechanisms contributing to COVID-19 severity in people with HIV (PWH) are poorly understood. We evaluated temporal changes in plasma proteins following SARS-CoV-2 infection and […]
March 1, 2023

Coronary Artery Plaque Composition and Severity Relate to the Inflammasome in People with Treated HIV

Abstract Inflammasome activation is increased in people with HIV (PWH), but its relationship with coronary plaque is poorly understood in this setting. In a large HIV […]
February 27, 2023

Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: a Longitudinal Analysis of REPRIEVE data

Abstract Weight gain with longer-term INSTI-based regimens remains unknown. Over 2-years of follow-up in REPRIEVE, INSTI use was associated with weight gain among those on an […]
February 27, 2023

Impact of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV

Abstract People with HIV (PWH) appear at higher risk for suboptimal pathogen responses and worse COVID-19 outcomes, but the effects of host factors and COVID-19 on […]
November 30, 2022

The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trial

Abstract Background REPRIEVE, the Randomized Trial to Prevent Vascular Events in HIV, is a multicenter, primary prevention trial evaluating whether a statin can prevent major cardiovascular […]
November 30, 2022

Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV

Abstract Objective To investigate relationships between Life’s Simple 7 (LS7), an assessment of cardiovascular health (CVH), and coronary plaque among people with HIV (PWH). Methods Coronary […]
September 27, 2022

Sex-Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation among People with HIV in the U.S.

Abstract Background Among people with HIV (PWH), sex-differences in presentations of atherosclerotic cardiovascular disease (ASCVD) may be influenced by differences in coronary plaque parameters, immune/inflammatory biomarkers, […]
September 1, 2022

Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV)

Abstract Background Cytomegalovirus (CMV) infection is thought to result in increased immune activation in people with human immunodeficiency virus (HIV, PWH). Although some data have linked […]
August 11, 2022

Diet in a Global Cohort of Adults with HIV at Low to Moderate Traditional Cardiovascular Disease Risk

Abstract Objective To characterize diet quality across a global cohort of people with HIV (PWH). Design Cross-sectional analysis. Methods Leveraging REPRIEVE data from baseline across five Global Burden […]
June 3, 2022

Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy

Abstract Background People with HIV (PWH) have subclinical coronary artery disease (CAD) despite low traditional atherosclerotic cardiovascular disease (ASCVD) risk scores. Coronary plaque in PWH presents […]
June 3, 2022

Asymptomatic SARS-CoV-2 Infection is Common among ART-treated People with HIV

Abstract Background Limited data are available regarding asymptomatic COVID-19 among people with HIV (PWH). Data on a representative subset of PWH enrolled in REPRIEVE, a global clinical trial […]
March 7, 2022

Geographical Differences in the Self-Reported Functional Impairment of People with HIV and Associations with Cardiometabolic Risk

Abstract Background We sought to explore multinational differences in functional status by Global Burden of Disease (GBD) regions in the REPRIEVE cohort. Methods REPRIEVE is a […]
March 3, 2022

Factors Associated with Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People with HIV on Antiretroviral Therapy

Abstract Background Among ART-treated people with HIV (PWH), persistent systemic immune activation contributes to atherogenesis, cardiovascular disease (CVD) events, and mortality. Factors associated with key immune […]
December 13, 2021

Prevalence and Correlates of Electrocardiographic Abnormalities in Adults with HIV: Insights from the REPRIEVE Trial

Abstract Background People with HIV (PWH) are at increased risk for cardiovasvular disease (CVD) and sudden cardiac death. Prior work has suggested an association between HIV […]
December 13, 2021

COVID-19 Vaccination Rates in a Global HIV Cohort

Abstract Little is known regarding COVID-19 vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates […]
December 13, 2021

Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus

Abstract Background Emerging data demonstrate that the use of integrase inhibitor (INSTI)-based antiretroviral treatment (ART) is associated with increased weight, but the cardiometabolic health consequences of […]
July 7, 2021

Cardiovascular Risk and Health Among People With HIV Eligible for Primary Prevention: Insights From the REPRIEVE Trial

Abstract Background In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and HIV-related factors may contribute to future CV events in persons with HIV […]
July 7, 2021

Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention

Key Points Question  What is the extent of coronary artery disease among people with well-controlled HIV and low to moderate risk of atherosclerotic cardiovascular disease (ASCVD), and […]
September 17, 2020

Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Co-Principal Investigators

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 […]
September 17, 2020

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial

Background: Patterns of antiretroviral therapy (ART) use and immunologic correlates vary globally, and contemporary trends are not well described. Methods: The REPRIEVE trial (Randomized Trial to […]
September 17, 2020

Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial

Background: Reproductive aging may contribute to cardiometabolic comorbid conditions. We integrated data on gynecologic history with levels of an ovarian reserve marker (anti-müllerian hormone [AMH)] to […]
September 17, 2020

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum

Abstract: Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are under-reported in HIV and cardiovascular […]
September 17, 2020

An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus

Background: Chronic kidney disease is a common comorbid condition among persons living with human immunodeficiency virus (PWH). We characterized baseline kidney function in the REPRIEVE (Randomized […]
September 17, 2020

Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE

Background: People with human immunodeficiency virus (PWH) are at risk for accelerated development of physical function impairment and frailty; both associated with increased risk of falls, […]
September 17, 2020

Myocardial Steatosis Among Antiretroviral Therapy–Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial

Background: People with human immunodeficiency virus (PWH) face increased risks for heart failure and adverse heart failure outcomes. Myocardial steatosis predisposes to diastolic dysfunction, a heart […]
September 17, 2020

Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination

Background: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is a multicenter, randomized, placebo-controlled trial, designed to test whether a statin medication can prevent […]
September 17, 2020

Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Background: Cardiovascular disease (CVD) is more frequent among people with HIV (PWH) and may relate to traditional and nontraditional factors, including inflammation and immune activation. A critical need […]
September 17, 2020

Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers

Background: The REPRIEVE Mechanistic Substudy (A5333s) represents the first large, randomized, CCTA-based assessment of the effects of a primary prevention strategy for CVD on high-risk CAD, […]
December 15, 2017

Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial

Background: Women’s under-representation in HIV and cardiovascular disease (CVD) research suggests a need for novel strategies to ensure robust representation of women in HIV-associated CVD research. […]